Ambrisentan
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB06403 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 23 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | pulmonary arteriovenous malformation (disease) | KG + DL |
| 2 | pulmonary arterial hypertension associated with congenital heart disease | KG + DL |
| 3 | pulmonary arterial hypertension associated with HIV infection | KG + DL |
| 4 | pulmonary arterial hypertension associated with schistosomiasis | KG + DL |
| 5 | pulmonary arterial hypertension associated with chronic hemolytic anemia | KG + DL |
| 6 | pulmonary arterial hypertension associated with connective tissue disease | KG + DL |
| 7 | malformation syndrome with odontal and/or periodontal component | KG + DL |
| 8 | hypotrichosis simplex of the scalp | KG + DL |
| 9 | hypertrichosis (disease) | KG + DL |
| 10 | syndrome with a Dandy-Walker malformation as major feature | KG + DL |
| 11 | isolated genetic hair shaft abnormality | KG + DL |
| 12 | Ambras type hypertrichosis universalis congenita | KG + DL |
| 13 | congenital hypotrichosis milia | KG + DL |
| 14 | diffuse alopecia areata | KG + DL |
| 15 | alopecia | KG + DL |
| 16 | telangiectasia, hereditary hemorrhagic, | KG + DL |
| 17 | pulmonary hypertension, primary | KG + DL |
| 18 | genetic alopecia | KG + DL |
| 19 | obsolete patella aplasia, coxa vara, and tarsal synostosis | KG + DL |
| 20 | idiopathic pulmonary arterial hypertension | KG + DL |
| 21 | pulmonary hypertension, primary, autosomal recessive | KG + DL |
| 22 | juvenile polyposis syndrome | KG + DL |
| 23 | dermatofibrosarcoma protuberans | KG + DL |
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.